Miniatura

Fitxers

729616.pdf (1.08 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-01-21

Llicència de publicació

cc by-nc-nd (c) Béguelin, Charles, 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/196211

Hepatitis delta infection among persons living with HIV in Europe

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1111/liv.15519

Resum

Background and aims: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes. Methods: All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti-HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV-positive and HDV-negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver-related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause-specific multivariable Cox regression. Results: Of 2793 HBsAg-positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%-17.1%) and 66% (132/200) of HDV-positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%-55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%-5.9%) among other participants. During a median follow-up of 10.8 years (interquartile range 5.6-17.8), 82 (34.6%) HDV-positive and 265 (20.1%) HDV-negative individuals died. 41.5% (34/82) of deaths were liver-related in HDV-positive individuals compared to 17.7% (47/265) in HDV-negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2-2.1), liver-related death (2.9, 1.6-5.0) and HCC (6.3, 2.5-16.0). Conclusion: We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver-related mortality and HCC incidence.

Matèries

Hepatitis vírica, VIH (Virus), Persones seropositives, Virus de l'hepatitis delta, Europa, Hepatitis B, Càncer de fetge

Matèries (anglès)

Viral hepatitis, HIV (Viruses), HIV-positive persons, Delta-associated agent, Europe, Hepatitis B, Liver cancer

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

BÉGUELIN, Charles, ATKINSON, Andrew, BOYD, Anders, FALCONER, Karolin, KIRKBY, Nikolai, SUTER RINIKER, Franziska, GÜNTHARD, Huldrych f., ROCKSTROH, Jürgen kurt, MOCROFT, Amanda, RAUCH, Andri, PETERS, Lars, WANDELER, Gilles, for EuroSIDA and SHCS, MIRÓ MEDA, José m. (josé maría). Hepatitis delta infection among persons living with HIV in Europe. _Liver International_. 2023. Vol. 43, núm. 4, pàgs. 819-828. [consulta: 24 de gener de 2026]. ISSN: 1478-3223. [Disponible a: https://hdl.handle.net/2445/196211]

Exportar metadades

JSON - METS

Compartir registre